Analysts’ Viewpoint on Mice Model Market Scenario
Since COVID-19 is linked with potential damage to organ systems, stakeholders in the healthcare industry are increasing research to develop vaccines and therapeutic agents against acute respiratory diseases. In many cases, animal testing has proven to be unreliable. Hence, the FDA (Food and Drug Administration) is predicted to implement the Modernization Act that would lift the compulsion of animal testing. Alternatives such as bio-printed organ models and human biology-based test methods hold promising potentials to replace ineffective mice models, thus inhibiting market growth. Due to these reasons, participants in the mice model market should unlock revenue opportunities in necessary healthcare applications such as for drug discovery and development. Animal models have and are anticipated to play an important role in the characterization of the pathophysiology of diseases and associated mechanisms of injury.
Increased research & development (R&D) in gene technology, fueled by the need of accurate and speedy treatment in the changing medical industry, is augmenting the growth of the global mice model market. The identification of genomic differences to predict drug response or drug resistance by patients can offer scope to design a personalized therapy tailored to the specific characteristics of a particular cancer. The Mouse Avatar and Co-clinical Trial concepts have the capability to transform the drug development and healthcare process.
The future possibilities for of the outbreak of COVID-19-like pandemics has brought stakeholders in the mice model market under great scrutiny by healthcare organizations. The high risk of morbidity and mortality associated with potential infectious outbreaks in the upcoming decade has heightened the need for vaccines and promising therapeutic agents to improve patient quality of life.
Since severe acute respiratory diseases can exacerbate into pneumonia, participants in the mice model market are expected to work closely with the World Health Organization (WHO) to increase research in vaccines and other therapeutic agents. Efforts are being made to prevent incidences of acute respiratory distress syndrome in patients.
Rising concerns about animal use for research and teaching purposes has been raised in nearly every part of the world in the past few years. A large number of international social organizations, such as PETA (People for the Ethical Treatment of Animals), believe that animal studies teach nothing about the health of humans, as human reactions to medications and illnesses are completely different from the reactions of mice and other animals.
Due to these reasons, stakeholders in the mice model market should target their R&D capabilities toward necessary healthcare activities such as in modern drug discovery. Animal models play an instrumental role in the development of safe & effective treatments and cures for diseases and/or associated symptoms. Other applications include drug target identification & evaluation of novel therapeutic agents for toxicity/safety, pharmacokinetics, pharmacodynamics, and efficacy.
Mice have been one of the most important research tools for basic and applied research in biomedical sciences, and this trend is anticipated to grow at a rapid rate. Besides providing precise correlation with human condition, the major advantage of mice models is the possibility of exploring precise gene-specific functions and various molecular events in living organisms. Combining mice models with advanced imaging technologies offer unique opportunities to understand the etiology and pathophysiology of human diseases.
Moreover, mice have been widely used in biomedical research to discover human diseases and to evaluate new drug candidates. Mouse research has led to major advances in treating a number of diseases and health conditions. For instance, experiments on mice models resulted in efficacious treatments for acute promyelocytic leukemia (APL) which was largely terminal.
The global mice model market has witnessed the development of several mice models in the last decade. Advanced mice models not only increase applications, but also acceptability of these models for increasing the availability of treatment for complex diseases.
Researchers are creating dynamic functional mice models for lung injury repair. This model would help in understanding some of the most complex aspects of lung diseases, and would be used for testing new therapies. The development of such models is likely to boost growth for the mice model market growth and increase funding for biomedical research. Furthermore, large pharmaceutical companies are focusing on entering into partnerships with institutes or companies specializing in the development of these models, providing a new source of funding and revenue generation.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 1.5 Bn |
|
Market Forecast Value in 2028 |
US$ 2.3 Bn |
|
Growth Rate (CAGR) |
6.2% |
|
Forecast Period |
2021–2028 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global mice model market is projected to reach a value of US$ 2.3 Bn by the end of 2028
Mice model market is anticipated to grow at a CAGR of 6.2% during the forecast period
North America accounted for a major share of the global mice model market
Mice model market is driven by increase in demand for mice models in personalized medicine due to development of personalized in vivo analysis mice models
Key players in the global mice model market include Charles River Laboratories, Crescendo Biologics Limited, Deltagen, Inc., GenOway S.A., Harlan Laboratories, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Mice Model Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Mice Model Market Analysis and Forecast, 2017–2028
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Developments
5.2. Overview of Mice Model Market
5.3. Technological Advancements
5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Mice Model Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2028
6.3.1. Transgenic Mice Model
6.3.2. Hybrid/Congenic Mice Model
6.3.3. Knockout Mice Model
6.3.4. Carcinogen-induced & Spontaneous Mice Model
6.3.5. Outbred Mice Model
6.3.6. Inbred Mice Model
6.3.7. Transplantation Mice Model
6.3.8. Conditioned/Surgically Modified Mice Model
6.4. Market Attractiveness Analysis, by Type
7. Global Mice Model Market Analysis and Forecast, by Specialty
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Specialty, 2017–2028
7.3.1. Immunology
7.3.2. Central Nervous System (CNS)
7.3.3. Oncology
7.3.4. Cardiovascular
7.3.5. Diabetes
7.3.6. Metabolism & Regulation
7.4. Market Attractiveness Analysis, by Specialty
8. Global Mice Model Market Analysis and Forecast, by Services
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Services, 2017–2028
8.3.1. Breeding & Rederivation Services
8.3.2. Cryopreservation & Cryorecovery Services
8.3.3. Quarantine Services
8.3.4. Genetic Testing Services
8.3.5. Model In-licensing Services
8.3.6. In Vivo & In Vitro Pharmacology Services
8.3.7. Genetically Engineered Model Services
8.3.8. Other Services (surgical and line rescue)
8.4. Market Attractiveness Analysis, by Services
9. Global Mice Model Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Mice Model Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2028
10.2.1. Transgenic Mice Model
10.2.2. Hybrid/Congenic Mice Model
10.2.3. Knockout Mice Model
10.2.4. Carcinogen-induced & Spontaneous Mice Model
10.2.5. Outbred Mice Model
10.2.6. Inbred Mice Model
10.2.7. Transplantation Mice Model
10.2.8. Conditioned/Surgically Modified Mice Model
10.3. Market Value Forecast, by Specialty, 2017–2028
10.3.1. Immunology
10.3.2. Central Nervous System (CNS)
10.3.3. Oncology
10.3.4. Cardiovascular
10.3.5. Diabetes
10.3.6. Metabolism & Regulation
10.4. Market Value Forecast, by Services, 2017–2028
10.4.1. Breeding & Rederivation Services
10.4.2. Cryopreservation & Cryorecovery Services
10.4.3. Quarantine Services
10.4.4. Genetic Testing Services
10.4.5. Model In-licensing Services
10.4.6. In Vivo & In Vitro Pharmacology Services
10.4.7. Genetically Engineered Model Services
10.4.8. Other Services (surgical and line rescue)
10.5. Market Value Forecast, by Country, 2017–2028
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Specialty
10.6.3. By Services
10.6.4. By Country
11. Europe Mice Model Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2028
11.2.1. Transgenic Mice Model
11.2.2. Hybrid/Congenic Mice Model
11.2.3. Knockout Mice Model
11.2.4. Carcinogen-induced & Spontaneous Mice Model
11.2.5. Outbred Mice Model
11.2.6. Inbred Mice Model
11.2.7. Transplantation Mice Model
11.2.8. Conditioned/Surgically Modified Mice Model
11.3. Market Value Forecast, by Specialty, 2017–2028
11.3.1. Immunology
11.3.2. Central Nervous System (CNS)
11.3.3. Oncology
11.3.4. Cardiovascular
11.3.5. Diabetes
11.3.6. Metabolism & Regulation
11.4. Market Value Forecast, by Services, 2017–2028
11.4.1. Breeding & Rederivation Services
11.4.2. Cryopreservation & Cryorecovery Services
11.4.3. Quarantine Services
11.4.4. Genetic Testing Services
11.4.5. Model In-licensing Services
11.4.6. In Vivo & In Vitro Pharmacology Services
11.4.7. Genetically Engineered Model Services
11.4.8. Other Services (surgical and line rescue)
11.5. Market Value Forecast, by Country/Sub-region, 2017–2028
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Specialty
11.6.3. By Services
11.6.4. By Country/Sub-region
12. Asia Pacific Mice Model Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2028
12.2.1. Transgenic Mice Model
12.2.2. Hybrid/Congenic Mice Model
12.2.3. Knockout Mice Model
12.2.4. Carcinogen-induced & Spontaneous Mice Model
12.2.5. Outbred Mice Model
12.2.6. Inbred Mice Model
12.2.7. Transplantation Mice Model
12.2.8. Conditioned/Surgically Modified Mice Model
12.3. Market Value Forecast, by Specialty, 2017–2028
12.3.1. Immunology
12.3.2. Central Nervous System (CNS)
12.3.3. Oncology
12.3.4. Cardiovascular
12.3.5. Diabetes
12.3.6. Metabolism & Regulation
12.4. Market Value Forecast, by Services, 2017–2028
12.4.1. Breeding & Rederivation Services
12.4.2. Cryopreservation & Cryorecovery Services
12.4.3. Quarantine Services
12.4.4. Genetic Testing Services
12.4.5. Model In-licensing Services
12.4.6. In Vivo & In Vitro Pharmacology Services
12.4.7. Genetically Engineered Model Services
12.4.8. Other Services (surgical and line rescue)
12.5. Market Value Forecast, by Country/Sub-region, 2017–2028
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Specialty
12.6.3. By Services
12.6.4. By Country/Sub-region
13. Latin America Mice Model Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type , 2017–2028
13.2.1. Transgenic Mice Model
13.2.2. Hybrid/Congenic Mice Model
13.2.3. Knockout Mice Model
13.2.4. Carcinogen-induced & Spontaneous Mice Model
13.2.5. Outbred Mice Model
13.2.6. Inbred Mice Model
13.2.7. Transplantation Mice Model
13.2.8. Conditioned/Surgically Modified Mice Model
13.3. Market Value Forecast, by Specialty, 2017–2028
13.3.1. Immunology
13.3.2. Central Nervous System (CNS)
13.3.3. Oncology
13.3.4. Cardiovascular
13.3.5. Diabetes
13.3.6. Metabolism & Regulation
13.4. Market Value Forecast, by Services, 2017–2028
13.4.1. Breeding & Rederivation Services
13.4.2. Cryopreservation & Cryorecovery Services
13.4.3. Quarantine Services
13.4.4. Genetic Testing Services
13.4.5. Model In-licensing Services
13.4.6. In Vivo & In Vitro Pharmacology Services
13.4.7. Genetically Engineered Model Services
13.4.8. Other Services (surgical and line rescue)
13.5. Market Value Forecast, by Country/Sub-region, 2017–2028
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Specialty
13.6.3. By Services
13.6.4. By Country/Sub-region
14. Middle East & Africa Mice Model Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2028
14.2.1. Transgenic Mice Model
14.2.2. Hybrid/Congenic Mice Model
14.2.3. Knockout Mice Model
14.2.4. Carcinogen-induced & Spontaneous Mice Model
14.2.5. Outbred Mice Model
14.2.6. Inbred Mice Model
14.2.7. Transplantation Mice Model
14.2.8. Conditioned/Surgically Modified Mice Model
14.3. Market Value Forecast, by Specialty, 2017–2028
14.3.1. Immunology
14.3.2. Central Nervous System (CNS)
14.3.3. Oncology
14.3.4. Cardiovascular
14.3.5. Diabetes
14.3.6. Metabolism & Regulation
14.4. Market Value Forecast, by Services, 2017–2028
14.4.1. Breeding & Rederivation Services
14.4.2. Cryopreservation & Cryorecovery Services
14.4.3. Quarantine Services
14.4.4. Genetic Testing Services
14.4.5. Model In-licensing Services
14.4.6. In Vivo & In Vitro Pharmacology Services
14.4.7. Genetically Engineered Model Services
14.4.8. Other Services (surgical and line rescue)
14.5. Market Value Forecast, by Country, 2017–2028
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Specialty
14.6.3. By Services
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Charles River Laboratories International, Inc.
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Crescendo Biologics Limited
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. Deltagen, Inc.
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. genOway S.A.
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Harbour Antibodies BV
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. Harlan Laboratories, Inc.
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. ImmunoGenes AG
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
15.2.8. The Jackson Laboratory
15.2.8.1. Company Overview
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Business Strategies
15.2.8.5. Recent Developments
15.2.9. Taconic Biosciences, Inc.
15.2.9.1. Company Overview
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Business Strategies
15.2.9.5. Recent Developments
15.2.10. TransGenic, Inc.
15.2.10.1. Company Overview
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Business Strategies
15.2.10.5. Recent Developments
List of Tables
Table 01: Global Mice Model Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 02: Global Mice Model Market Value (US$ Mn) Forecast, by Specialty, 2017‒2031
Table 03: Global Mice Model Market Value (US$ Mn) Forecast, by Services, 2017‒2031
Table 04: Global Mice Model Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Mice Model Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Mice Model Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 07: North America Mice Model Market Value (US$ Mn) Forecast, by Specialty, 2017‒2031
Table 08: North America Mice Model Market Value (US$ Mn) Forecast, by Services, 2017‒2031
Table 09: Europe Mice Model Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Mice Model Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 11: Europe Mice Model Market Value (US$ Mn) Forecast, by Specialty, 2017‒2031
Table 12: Europe Mice Model Market Value (US$ Mn) Forecast, by Services, 2017‒2031
Table 13: Asia Pacific Mice Model Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Mice Model Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 15: Europe Mice Model Market Value (US$ Mn) Forecast, by Specialty, 2017‒2031
Table 16: Europe Mice Model Market Value (US$ Mn) Forecast, by Services, 2017‒2031
Table 17: Latin America Mice Model Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Mice Model Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 19: Latin America Mice Model Market Value (US$ Mn) Forecast, by Specialty, 2017‒2031
Table 20: Latin America Mice Model Market Value (US$ Mn) Forecast, by Services, 2017‒2031
Table 21: Middle East & Africa Mice Model Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Mice Model Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 23: Middle East & Africa Mice Model Market Value (US$ Mn) Forecast, by Specialty, 2017‒2031
Table 24: Middle East & Africa Mice Model Market Value (US$ Mn) Forecast, by Services, 2017‒2031
List of Figures
Figure 01: Global Mice Model Market Value (US$ Mn) Forecast, 2017–2028
Figure 02: Global Mice Model Market Value Share, by Type, 2020
Figure 03: Global Mice Model Market Value Share, by Specialty, 2020
Figure 04: Global Mice Model Market Value Share, by Services, 2020
Figure 05: Global Mice Model Market Value Share, by Region, 2020
Figure 06: Global Mice Model Market, by Type, 2017 and 2028
Figure 07: Global Mice Model Market Attractiveness Analysis, by Type, 2020–2028
Figure 08: Global Mice Model Market (US$ Mn), by Transgenic Mice Model, 2017–2028
Figure 09: Global Mice Model Market (US$ Mn), by Hybrid/Congenic Mice Model, 2017–2028
Figure 10: Global Mice Model Market (US$ Mn), by Knockout Mice Model, 2017–2028
Figure 11: Global Mice Model Market (US$ Mn), by Carcinogen-induced & Spontaneous Mice Model, 2017–2028
Figure 12: Global Mice Model Market (US$ Mn), by Outbred Mice Model, 2017–2028
Figure 13: Global Mice Model Market (US$ Mn), by Inbred Mice Model, 2017–2028
Figure 14: Global Mice Model Market (US$ Mn), by Transplantation Mice Model, 2017–2028
Figure 15: Global Mice Model Market (US$ Mn), by Conditioned/Surgically Modified Mice Model, 2017–2028
Figure 16: Global Mice Model Market, by Specialty, 2017 and 2028
Figure 17: Global Mice Model Market Attractiveness Analysis, by Specialty, 2020–2028
Figure 18: Global Mice Model Market (US$ Mn), by Immunology, 2017–2028
Figure 19: Global Mice Model Market (US$ Mn), by Central Nervous System (CNS), 2017–2028
Figure 20: Global Mice Model Market (US$ Mn), by Oncology, 2017–2028
Figure 21: Global Mice Model Market (US$ Mn), by Cardiovascular, 2017–2028
Figure 22: Global Mice Model Market (US$ Mn), by Diabetes, 2017–2028
Figure 23: Global Mice Model Market Attractiveness Analysis, by Services, 2020–2028
Figure 24: Global Mice Model Market (US$ Mn), by Cryopreservation & Cryorecovery Services, 2017–2028
Figure 25: Global Mice Model Market (US$ Mn), by Quarantine Services, 2017–2028
Figure 26: Global Mice Model Market (US$ Mn), by Genetic Testing Services, 2017–2028
Figure 27: Global Mice Model Market (US$ Mn), by Model In-licensing Services, 2017–2028
Figure 28: Global Mice Model Market (US$ Mn), by In Vivo & In Vitro Pharmacology Services, 2017–2028
Figure 29: Global Mice Model Market (US$ Mn), by Genetically Engineered Model Services, 2017–2028
Figure 30: Global Mice Model Market (US$ Mn), Other services (surgical and line rescue), 2017–2028
Figure 31: North America Mice Model Market Value (US$ Mn) Forecast, 2017–2028
Figure 32: North America Mice Model Market Value Share Analysis, by Country, 2017 and 2028
Figure 33: North America Mice Model Market, by Type, 2017 and 2028
Figure 34: North America Mice Model Market Attractiveness Analysis, by Type, 2020–2028
Figure 35: North America Mice Model Market, by Specialty, 2017 and 2028
Figure 36: North America Mice Model Market Attractiveness Analysis, by Specialty, 2020–2028
Figure 37: North America Mice Model Market, by Services, 2017 and 2028
Figure 38: North America Mice Model Market Attractiveness Analysis, by Services, 2020–2028
Figure 39: Europe Mice Model Market Value (US$ Mn) Forecast, 2017–2028
Figure 40: Europe Mice Model Market Value Share Analysis, by Country/Sub-region, 2017 and 2028
Figure 41: Europe Mice Model Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Figure 42: Europe Mice Model Market, by Type, 2017 and 2028
Figure 43: Europe Mice Model Market Attractiveness Analysis, by Type, 2020–2028
Figure 44: Europe Mice Model Market, by Specialty, 2017 and 2028
Figure 45: Europe Mice Model Market Attractiveness Analysis, by Specialty, 2020–2028
Figure 46: Europe Mice Model Market, by Services, 2017 and 2028
Figure 47: Europe Mice Model Market Attractiveness Analysis, by Services, 2020–2028
Figure 48: Asia Pacific Mice Model Market Value (US$ Mn) Forecast, 2017–2028
Figure 49: Asia Pacific Mice Model Market Value Share Analysis, by Country/Sub-region, 2017 and 2028
Figure 50: Asia Pacific Mice Model Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Figure 51: Asia Pacific Mice Model Market, by Type, 2017 and 2028
Figure 52: Asia Pacific Mice Model Market Attractiveness Analysis, by Type, 2020–2028
Figure 53: Asia Pacific Mice Model Market, by Specialty, 2017 and 2028
Figure 54: Asia Pacific Mice Model Market Attractiveness Analysis, by Specialty, 2020–2028
Figure 55: Asia Pacific Mice Model Market, by Services, 2017 and 2028
Figure 56: Asia Pacific Mice Model Market Attractiveness Analysis, by Services, 2020–2028
Figure 57: Latin America Mice Model Market Value (US$ Mn) Forecast, 2017–2028
Figure 58: Latin America Mice Model Market Value Share Analysis, by Country/Sub-region, 2017 and 2028
Figure 59: Latin America Mice Model Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Figure 60: Latin America Mice Model Market, by Type, 2017 and 2028
Figure 61: Latin America Mice Model Market Attractiveness Analysis, by Type, 2020–2028
Figure 62: Latin America Mice Model Market, by Specialty, 2017 and 2028
Figure 63: Latin America Mice Model Market Attractiveness Analysis, by Specialty, 2020–2028
Figure 64: Latin America Mice Model Market, by Services, 2017 and 2028
Figure 65: Latin America Mice Model Market Attractiveness Analysis, by Services, 2020–2028
Figure 66: Middle East & Africa Mice Model Market Value (US$ Mn) Forecast, 2017–2028
Figure 67: Middle East & Africa Mice Model Market Value Share Analysis, by Country/Sub-region, 2017 and 2028
Figure 68: Middle East & Africa Mice Model Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Figure 69: Middle East & Africa Mice Model Market, by Type, 2017 and 2028
Figure 70: Middle East & Africa Mice Model Market Attractiveness Analysis, by Type, 2020–2028
Figure 71: Middle East & Africa Mice Model Market, by Specialty, 2017 and 2028
Figure 72: Middle East & Africa Mice Model Market Attractiveness Analysis, by Specialty, 2020–2028
Figure 73: Middle East & Africa Mice Model Market, by Services, 2017 and 2028
Figure 74: Middle East & Africa Mice Model Market Attractiveness Analysis, by Services, 2020–2028
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Mice Model Market
